中国血液净化

›› 2010, Vol. 9 ›› Issue (1): 12-18.

• 临床研究 • 上一篇    下一篇

高通量血液透析对维持性血液透析患者生存率影响的Meta分析

姜国涛 许 戎 左 力   

  1. 大学第一医院肾脏内科
  • 收稿日期:2009-10-20 修回日期:1900-01-01 出版日期:2010-01-12 发布日期:2010-01-12
  • 通讯作者: 左力

The meta analysis of influence of high flux hemodialysis on survival rate of maintenance hemodialysis patients

JIANG Guo-tao1, XU Rong2, ZUO Li   

  1. 1Department of nephrology of the fifth center hospital of tianjin，tianjin 300450; 2Institute of Nephrology, Peking University First Hospital, Beijing, 100034.
  • Received:2009-10-20 Revised:1900-01-01 Online:2010-01-12 Published:2010-01-12

RichHTML

1

PDF

227

摘要： 【摘要】目的 已知在某些特殊人群，高通量血液透析(high flux hemodialysis HFHD)能改善维持性血液透析(maintenance hemodialysis, MHD)患者生存率。本研究拟分析总体来说，高通量透析是否改善MHD患者生存率。方法 检索了Pubmed/Medline、EMBASE和Cochrane Library 电子数据库的HFHD对MHD患者生存率影响的随机对照试验(randomized controlled trials RCT) 和前瞻性对照试验(prospective controlled trials, PCT)，使用优势比进行计算。 结果 3个RCT和2个PCT共3609名患者被纳入本次研究：5个试验均比较了HFHD与低通量血液透析(low flux hemodialysis LFHD)对患者生存率的影响。与LFHD组相比，HFHD组患者的生存率没有得到改善(固定效应模型，OR=1.20, Z=1.85, P=0.06，I2=68.1%)。HFHD组在患者平均住院率、心血管死亡率方面与LFHD组无明显差异。 结论 HFHD不能提高MHD患者生存率，不能降低MHD患者平均住院率和心血管死亡率。

关键词: 高通量血液透析, 生存率, Meta分析

Abstract:

【Abstract】Objective To evaluate the effect of high-flux hemodialysis (HFHD) in the survival rate of maintenance hemodialysis (MHD) patients. Methods randomized controlled trials (RCT) and prospective controlled trials (PCT) studying the effect of HFHD on survival rate of MHD patients were searched in the Pubmed / Medline, EMBASE、and Cochrane Library electronic databases, then the odds ratio was calculated. Results 3609 patients in 3 RCT and 2 PCT were included in this study: the effect of survival rate was compared in the HFHD and LFHD group. Compared with the LFHD group, the survival rate of HFHD group wasn抰 improved (Fixed effect model, OR=1.20, Z=1.85, P=0.06，I2=68.1%). There were no significant difference of average admission rate and cardivascular mortality rate between HFHD group and LFHD group. Conclusions HFHD may not improve the survival rate of MHD patients, and it may not reduce the average admission rate and cardiovascular mortality rate of MHD patients.